.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,246,979

« Back to Dashboard

Claims for Patent: 8,246,979

Title:Transdermal delivery system for the administration of rotigotine
Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.
Inventor(s): Schacht; Dietrich Wilhelm (Koln, DE), Hannay; Mike (Wachtberg-Villiprott, DE), Wolff; Hans-Michael (Monheim, DE)
Assignee: UCB Pharma GmbH (Monheim, DE)
Application Number:10/623,864
Patent Claims: 1. A transdermal delivery system (TDS) comprising a backing layer and a self-adhesive matrix containing rotigotine, wherein the self-adhesive matrix comprises a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form is incorporated, and wherein said free base has been isolated prior to its incorporation into the matrix, (2) which comprises a multitude of microreservoirs within the matrix, said microreservoirs containing rotigotine free base, (3) which is permeable to the free base of rotigotine, (4) which is substantially impermeable to the protonated form of rotigotine, and (5) wherein all the microreservoirs have a maximum diameter that is less than the thickness of the matrix; and wherein the backing layer is inert to the components of the matrix.

2. The TDS of claim 1, wherein the microreservoirs have a mean diameter in the range of 0.5 to 20 .mu.m.

3. The TDS of claim 1, wherein the self-adhesive matrix is free of particles that can absorb salts of rotigotine at the TDS/skin interface.

4. The TDS of claim 1, wherein the self-adhesive matrix comprises a silicone pressure sensitive adhesive.

5. The TDS of claim 1, wherein the self-adhesive matrix comprises two or more silicone pressure sensitive adhesives as the main adhesive components.

6. The TDS of claim 5, wherein the two or more silicone pressure sensitive adhesives comprise a blend of a high tack silicone pressure sensitive adhesive comprising polysiloxane with a resin and a medium tack silicone pressure sensitive adhesive comprising polysiloxane with a resin.

7. A method for treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the TDS of claim 1 to the skin of the patient.

8. The TDS of claim 1, wherein the microreservoirs additionally contain at least one crystallization inhibitor comprising soluble polyvinylpyrrolidone, a copolymer of polyvinylpyrrolidone and vinyl acetate, polyethylene glycol, polypropylene glycol, glycerol, a fatty acid ester of glycerol and/or a copolymer of ethylene and vinyl acetate.

9. The TDS of claim 8, wherein the at least one crystallization inhibitor comprises soluble polyvinylpyrrolidone.

10. The TDS of claim 1, comprising within the matrix 10.sup.3 to 10.sup.9 microreservoirs per cm.sup.2 of the surface of the matrix.

11. The TDS of claim 1, comprising within the matrix 10.sup.6 to 10.sup.9 microreservoirs per cm.sup.2 of the surface of the matrix.

12. The TDS of claim 1, wherein the microreservoirs have a maximum diameter not greater than 35 .mu.m.

13. The TDS of claim 1, wherein the microreservoirs have a maximum diameter of 2.5 to 30 .mu.m.

14. The TDS of claim 1, wherein any amount of rotigotine salt present comprises less than 5% w/w of the self-adhesive matrix.

15. The TDS of claim 1, wherein any amount of rotigotine salt present comprises less than 2% w/w of the self-adhesive matrix.

16. The TDS of claim 1, wherein any amount of rotigotine salt present comprises less than 1% of the self-adhesive matrix.

17. The TDS of claim 1, wherein the free base of rotigotine has been isolated in solid form prior to the incorporation in the matrix.

18. The TDS of claim 1, wherein the microreservoirs containing rotigotine free base distributed in the matrix have a mean diameter between 1-40% of the thickness of the matrix.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc